CIPLANSECipla Limited· PharmaceuticalsLowNeutral
Announced Tue, 13 May · 14:21 IST

Cipla Limited has informed the Exchange regarding a press release dated May 13, 2025, titled "Press release ".

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Cipla reported strong Q4 FY25 results with consolidated revenue of INR 6,730 Cr, up 9% YoY, and PAT of INR 1,222 Cr, up 30% YoY. EBITDA margin expanded 150 bps to 22.8%. For the full year FY25, revenue grew 8% YoY to INR 27,548 Cr, EBITDA grew 14% to INR 7,128 Cr (25.9% margin), and PAT surged 28% to INR 5,273 Cr. North America posted an all-time high annual revenue of $934 Mn, while One Africa grew 15% YoY in USD and Emerging Markets & Europe grew 16% YoY in Q4. The company declared a final dividend of ₹13 per share plus a special ₹3 dividend celebrating its 90th anniversary, totaling ₹16 per share. The company holds a strong net cash position of INR 10,369 Cr with R&D spend at INR 426 Cr (6.3% of sales).

Likely market impact

Strong margin expansion, robust PAT growth of 28% for FY25, record North America revenue, and a special 90th-anniversary dividend signal healthy fundamentals and shareholder-friendly capital allocation. Positive for investor sentiment and likely supportive of the stock price.